Welcome to our dedicated page for Corbus Pharmaceu news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceu stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage oncology and obesity company whose news flow is driven by clinical trial progress, regulatory milestones, and capital markets activity. The company regularly issues press releases on Phase 1 and Phase 2 data for its investigational drug candidates, as well as updates on financing transactions and participation in major healthcare conferences.
Investors following CRBP news can expect detailed updates on CRB-701, Corbus’ Nectin-4–targeting antibody-drug conjugate being studied in a multi-center Phase 1/2 trial in advanced solid tumors such as head and neck squamous cell carcinoma, cervical cancer, and metastatic urothelial cancer. News items have highlighted objective response rates, disease control rates, safety findings, and Fast Track designations granted by the U.S. Food and Drug Administration. Corbus also announces presentations of CRB-701 data at scientific meetings like the European Society for Medical Oncology Congress and associated key opinion leader events.
Another major news theme is the company’s obesity program, particularly CRB-913, a highly peripherally restricted oral CB1 receptor inverse agonist. Corbus has reported results from a Phase 1a SAD/MAD study in the United States, including safety, tolerability, pharmacokinetic data, and emerging evidence of weight loss in people with obesity. Subsequent news covers the initiation and design of the 12‑week CANYON‑1 Phase 1b study in obese, non-diabetic participants.
Corbus’ news feed also includes quarterly financial results, preliminary financial updates via Form 8‑K, and announcements of underwritten public offerings of common stock and pre-funded warrants. In addition, the company frequently discloses its participation in investor conferences and healthcare symposia, where it presents corporate overviews and engages in one-on-one investor meetings. Bookmarking the CRBP news page on Stock Titan allows readers to track these clinical, regulatory, and financing developments in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is set to host a virtual 'Meet the Expert' event on April 25, 2023, at 11:00 AM ET. The focus will be on CRB-601, an anti-integrin monoclonal antibody targeting Transforming Growth Factor β (TGFβ) in oncology. Featuring notable researchers Dr. Jeffrey Clarke and Dr. Joan Seoane, the session will highlight CRB-601's potential to inhibit tumor growth, as evidenced in non-clinical studies. The company plans to submit an Investigational New Drug (IND) application for CRB-601 in the latter half of 2023. This initiative underscores Corbus's commitment to advancing precision oncology by innovating treatments for serious illnesses.
Corbus Pharmaceuticals (NASDAQ: CRBP) recently showcased promising pre-clinical data for its drug CRB-601 at the 2023 AACR annual meeting. The study revealed that CRB-601, an avβ8 blocking antibody, demonstrated dose-dependent antitumor activity and significantly enhanced the efficacy of anti-PD-1 immunotherapy. Additionally, the IND submission for CRB-601 is on track for the second half of 2023. The findings highlighted a notable increase in immune cell populations within tumors, along with a blockade of the TGFβ signaling pathway. The combination therapy showed substantial tumor growth inhibition in pre-clinical models, suggesting a strong potential for CRB-601 in cancer treatment.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that pre-clinical data for its avβ8 blocking antibody, CRB-601, has been accepted for presentation at the 2023 American Association for Cancer Research annual meeting in Orlando, FL, from April 14-19, 2023.
The poster presentation is titled CRB-601, an avβ8 blocking antibody, prevents activation of TGFβ and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment and will occur on April 16, 2023, from 1:30 PM - 5:00 PM.
Corbus focuses on innovative treatments targeting well-understood biological pathways in cancer therapy.